Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1998-09-10
2002-03-12
Eyler, Yvonne (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388220, C530S350000, C530S351000, C435S069100, C436S501000, C536S023500, C536S024310
Reexamination Certificate
active
06355779
ABSTRACT:
BACKGROUND OF THE INVENTION
The term “cytokines” encompasses a diverse group of soluble proteins that are released by one type of cell and mediate a biological effect on another cell type. Biological activities exhibited by cytokines include control of proliferation, growth, and differentiation of various cell types, among which are cells of the hematopoietic or immune systems.
Examples of cytokines include the interleukins (e.g., interleukins 1 through 12), the interferons (IFN&agr;, IFN&bgr;, and IFN&agr;), tumor necrosis factor (TNF&agr; and TNF&bgr;), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and colony stimulating factors. Examples of colony stimulating factors (CSF), which control growth and differentiation of hematopoietic cells, are granulocyte-CSF (G-CSF), granulocyte-macrophage-CSF (GM-CSF), macrophage-CSF (M-CSF or CSF-1), mast cell growth factor (MGF), and erythropoietin (EPO).
The biological activity of cytokines generally is mediated by binding of the cytokine to a receptor specific for that cytokine, located on the surface of target cells. Much research has been directed to identifying receptor(s) that bind a given cytokine (often referred to as the “ligand” for the receptor in question), and exploring the roles that endogenous ligands and receptors play in vivo.
One family of cytokine receptors includes two different TNF receptors (Type I and Type II) (Smith et al.,
Science
248:1019, 1990) and Schall et al.,
Cell
61:361, 1990); nerve growth factor receptor (Johnson et al.,
Cell
47:545, 1986); B cell antigen CD40 (Stamenkovic et al.,
EMBO J.
8:1403, 1989); T cell antigen OX40 (Mallett et al.,
EMBO J.
9:1063, 1990); human Fas antigen (Itoh et al.,
Cell
66:233, 1991); and murine receptor 4-1BB (Kwon et al.,
Cell. Immunol.
121:414, 1989) [Kwon et al. I] and Kwon et al.,
Proc. Natl. Acad. Sci. USA
86:1963, 1989 [Kwon et al. II]).
Expression of murine 4-1BB is induced by concanavalin A (con A) in spleen cells, cloned helper T cells, cytolytic T cells, and cytolytic T cell hybridomas (Kwon et al. II). Murine 4-1BB cDNA was isolated from a cDNA library made from induced RNA isolated from both a helper T cell line and a cytotoxic T cell line (Kwon et al. II). The nucleotide sequence of the isolated cDNA is presented in Kwon et al. II, along with the amino acid sequence encoded thereby. The murine 4-1BB protein comprises 256 amino acids, including a putative leader sequence, trans-membrane domain and a number of other features common to cell membrane bound receptor proteins. Regarding a putative human 4-1BB protein, neither amino acid nor nucleotide sequence information is known for any such protein.
No ligand that would bind 4-1BB and transduce a signal through the 4-1BB receptor is known. Thus, there is a need in the art to determine whether a novel protein functioning as a ligand for 4-1BB exists, and, if so, to isolate and characterize the 4-1BB ligand protein.
SUMMARY OF THE INVENTION
A novel cytokine designated 4-1BB ligand (4-1BB-L) is disclosed herein. 4-1BB-L polypeptides bind to the cell surface receptor designated 4-1BB. Human 4-1BB is also provided by the present invention.
The present invention provides purified 4-1BB-L polypeptides, exemplified by the murine and human 4-1BB-L proteins disclosed herein, and purified human 4-1BB polypeptides. Isolated DNA sequences encoding 4-1BB-L or human 4-1BB, recombinant expression vectors comprising the isolated DNA, and host cells transformed with the expression vectors are provided by the present invention, along with methods for producing 4-1BB-L and human 4-1BB by cultivating the transformed host cells. Antibodies that are immunoreactive with 4-1BB-L or human 4-1BB also are provided.
REFERENCES:
patent: 4675285 (1987-06-01), Clark et al.
patent: 5030576 (1991-07-01), Dull et al.
patent: 5217880 (1993-06-01), Mitta et al.
patent: 5312733 (1994-05-01), MacLeod
Kwon, B. and Weissman, S., “cDNA sequences of two inducible T-cell genes”,Proc. Natl. Acad. Sci. USA, 86:1963-1967, Mar. 1989.
Kwon, B. et al., “Expression Characteristics of Two Potential T Cell Mediator Genes”,Cellular Immunology, 121;414-422, 1989.
Kwon, B. et al., “Isolation and initial characterization of multiple species of T-lymphocyte subset cDNA clones,”Proc. Natl. Acad. Sc.USA, 84:2896-2900, May 1987.
Pollok, K. et al., “Inducible T Cell Antigen 4-1BB”,The Journal of Immunology, 150:771-781, Feb. 1, 1993.
Mallet, S. and Barclay, A.N., “A new superfamily of cell surface proteins related to the nerve growth factor receptor”,Immunology Today, 12:220-223, 1991.
Schwartz et al., “cDNA Sequence Tissue Distribution and Regulation of Expression of a New Member of the Human TNF-NGF Recepter Family”,Arthritis Rheum. 35 (9 Suppl.), Abstract D63, p. S224, 1992.
Schwartz et al., “Identification of a New Member of the Human Nerve Growth Factor/Tumor Necrosis Factor Receptor Family,”J. Immunology 150: 298A, Abstract No. 1705, 1993.
Chalupny, N. et al., “T-cell activation molecule 4-1BB binds to extracellular matrix proteins”,Proc. Natl. Acad. Sci.USA, 89:10360-64, Nov. 1992.
Flanagan, J. and Leder, P., “The kit Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts”,Cell 63:185-194, Oct. 5, 1990.
Aruffo, A. and Seed, B., “Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system”,Proc. Natl. Acad. Sci. USA 84: 8573-8577, Dec. 1987.
Capon, D., et al., “Designing CD4 immunoadhesins for AIDS therapy”,Nature 337: 525-531, Feb. 9, 1989.
Steele, R.E., “Factor hunting made easier”,TIBS16:125-126, Apr. 1991.
Armitage, R., et al., “Molecular and biological characterization of a murine ligand for CD40”,Nature 357: 80-82 (1992).
Hollenbaugh, D., et al., “The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity”,The Embo Journal 11: 4313-4321 (1992).
Ohtsuka, E., et al., “An Alternative Approach to Deoxyoligonucleotides as Hybridization Probes by Insertion of Neoxyinosine at Ambiguous Codon Positions,”Journal of Biol. Chemistry 260: (5) 2605-2608, 1985.
Frohman, M., et al., “Rapid production of full-length cDNAs form rare transcripts: Amplification using a single gene-specific oligonucleotide primer,”Proc. Natl. Acad. Sci. USA, 85:8998-9002, 1998.
Alderson Mark R.
Goodwin Raymond G.
Smith Craig A.
Brannock Michael
Eyler Yvonne
Henry Janis C.
Immunex Corporation
Jones Simone L.
LandOfFree
Cytokine designated 4-1BB ligand antibodies and human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytokine designated 4-1BB ligand antibodies and human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytokine designated 4-1BB ligand antibodies and human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2835805